TABLE 5.
Predicted MN titers as estimates of protective effectiveness based on slope and intercept estimates from Deming regressiona
| Vaccine | Strain | Titer |
||
|---|---|---|---|---|
| Predicted MN (at HI 1:10) |
Predicted MN (at HI 1:40) |
Predicted MN (at HI 1:110) |
||
| TIVc | A/H1N1 | 13 | 65 | 207 |
| A/H3N2 | 10 | 35 | 88 | |
| B | 17 | 119 | 492 | |
| TIVe | A/H1N1 | 26 | 151 | 546 |
| A/H3N2 | 9 | 32 | 80 | |
| B | 17 | 119 | 495 | |
| aQIV | A/H3N2 | 9 | 47 | 155 |
| B | 8 | 42 | 137 | |
| QIV | A/H3N2 | 11 | 52 | 163 |
| B | 9 | 47 | 151 | |
a
Abbreviations: aQIV, adjuvanted quadrivalent influenza vaccine; MN, microneutralization; QIV, nonadjuvanted quadrivalent influenza vaccine; TIVc, cell-derived trivalent influenza vaccine; TIVe, egg-derived trivalent influenza vaccine.